-
Shandong Luoxin Pharmaceutical Partners with Xbiome to Access Microbiome Transplantation Technology
•
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a pharmaceutical company based in China, has entered into a strategic partnership with Xbiome, a compatriot firm specializing in AI-based microbiome drug development. This collaboration grants Luoxin access to Xbiome’s advanced intestinal microbiota transplantation medical technology, marking a significant step in…
-
Shandong Luoxin’s LX-039 Demonstrates Promise in Phase I Oncology Study at ESMO
•
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a China-based pharmaceutical innovator, has published data from a Phase I clinical study for its novel anti-tumor drug, LX-039. This oral selective estrogen receptor modulator (SERD) was in the spotlight at the European Society for Medical Oncology (ESMO) Congress 2023, where…
